Voveran SR: Sustained Relief for Chronic Musculoskeletal Pain
| Product dosage: 50mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 90 | $0.49 | $44.20 (0%) | 🛒 Add to cart |
| 120 | $0.47 | $58.93 $56.25 (5%) | 🛒 Add to cart |
| 180 | $0.44 | $88.40 $79.36 (10%) | 🛒 Add to cart |
| 270 | $0.42 | $132.60 $113.51 (14%) | 🛒 Add to cart |
| 360 | $0.42
Best per pill | $176.80 $150.68 (15%) | 🛒 Add to cart |
Synonyms | |||
Voveran SR (Diclofenac Sodium Sustained Release) is a prescription nonsteroidal anti-inflammatory drug (NSAID) specifically formulated for the long-term management of moderate to severe pain and inflammation associated with chronic musculoskeletal and joint disorders. Its advanced sustained-release technology ensures a steady plasma concentration, providing around-the-clock symptomatic relief, improving functional capacity, and enhancing quality of life for patients with persistent inflammatory conditions. It is particularly effective in osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis, where consistent drug delivery is critical for therapeutic efficacy.
Features
- Contains Diclofenac Sodium in a 100mg sustained-release tablet formulation
- Utilizes a hydrophilic matrix system for controlled, pH-independent release
- Designed for once-daily dosing due to extended pharmacokinetic profile
- Bioavailability of approximately 54-60% due to first-pass metabolism
- Peak plasma concentration (Tmax) achieved in 5-6 hours post-administration
- Plasma half-life of approximately 12 hours in sustained-release form
- Excipients include lactose, hypromellose, povidone, and magnesium stearate
Benefits
- Provides continuous 24-hour analgesia and anti-inflammatory action, reducing breakthrough pain episodes
- Enhances patient compliance through convenient once-daily dosing regimen
- Improves joint mobility and reduces morning stiffness in arthritic conditions
- Minimizes peak-trough fluctuations, lowering risk of concentration-dependent side effects
- Supports long-term inflammatory control, potentially slowing radiographic progression in some arthritis subtypes
- Facilitates restorative sleep by controlling nighttime pain and discomfort
Common use
Voveran SR is primarily indicated for the management of chronic inflammatory and degenerative forms of rheumatism, including rheumatoid arthritis, osteoarthritis, and ankylosing spondylitis. It is also prescribed for acute musculoskeletal disorders such as periarthritis (e.g., frozen shoulder), tendinitis, tenosynovitis, bursitis, and low back pain. Off-label uses may include management of pain in gout attacks (though not first-line) and certain dental pain conditions. It is not recommended for peri-operative pain or acute injury management where immediate-release formulations are more appropriate.
Dosage and direction
The recommended adult dosage is one 100mg sustained-release tablet once daily, taken whole with a full glass of water during or after meals to minimize gastrointestinal irritation. Tablets must not be crushed, chewed, or broken, as this disrupts the sustained-release mechanism and may cause dose dumping. For elderly patients or those with mild hepatic impairment, initiation with a lower dose (e.g., 50mg immediate-release formulation) may be considered. Duration of therapy should be periodically reevaluated, with treatment lasting no longer than necessary based on regular clinical assessment.
Precautions
Use with caution in patients over 65 years, as they exhibit increased susceptibility to NSAID-related adverse effects. Monitor renal function in patients with pre-existing renal impairment, heart failure, hepatic dysfunction, or volume depletion. Assess cardiovascular risk profile before initiation, particularly in patients with hypertension, established heart disease, or cerebrovascular disease. Conduct periodic liver function tests during prolonged therapy. Avoid concomitant use with other NSAIDs, including COX-2 selective inhibitors. Use the lowest effective dose for the shortest duration consistent with treatment goals.
Contraindications
Hypersensitivity to diclofenac, other NSAIDs, or any excipients in the formulation. Patients with active peptic ulceration, gastrointestinal bleeding, or perforation. Severe hepatic, renal, or cardiac failure. Third trimester of pregnancy. History of asthma, urticaria, or allergic-type reactions precipitated by NSAIDs. Established ischemic heart disease, peripheral arterial disease, or cerebrovascular disease. Inflammatory bowel disease. Co-administration with other NSAIDs, including selective COX-2 inhibitors.
Possible side effects
Common (≥1/100): Epigastric pain, dyspepsia, nausea, diarrhea, headache, dizziness. Uncommon (≥1/1000): Gastrointestinal ulceration, vomiting, flatulence, constipation, elevated liver enzymes, rash, pruritus, fluid retention, hypertension. Rare (≥1/10,000): Gastrointestinal hemorrhage, pancreatitis, hepatitis, bronchospasm, anaphylactoid reactions, photosensitivity, acute renal failure, interstitial nephritis, thrombocytopenia, agranulocytosis, aplastic anemia. Very rare: Severe cutaneous adverse reactions (SCARs) including Stevens-Johnson syndrome, toxic epidermal necrolysis.
Drug interaction
Significant interactions occur with anticoagulants (increased bleeding risk), antihypertensives (reduced efficacy), diuretics (risk of acute kidney injury), lithium (elevated serum levels), methotrexate (increased toxicity), cyclosporine (nephrotoxicity), and other NSAIDs (additive toxicity). Concurrent use with SSRIs or corticosteroids increases gastrointestinal bleeding risk. May reduce efficacy of diuretics and ACE inhibitors. Caution with phenytoin, digoxin, and hypoglycemic agents due to potential displacement from protein binding sites.
Missed dose
If a dose is missed, take it as soon as remembered unless it is nearly time for the next scheduled dose. Do not double the dose to make up for a missed one. Maintaining consistent dosing intervals is important for stable therapeutic levels, but occasional missed doses are unlikely to significantly impact overall efficacy due to the sustained-release formulation’s pharmacokinetic profile.
Overdose
Symptoms may include headache, nausea, vomiting, epigastric pain, gastrointestinal bleeding, drowsiness, dizziness, tinnitus, syncope, or convulsions. Rarely, hypertension, acute renal failure, respiratory depression, or coma may occur. There is no specific antidote. Management involves supportive care and symptomatic treatment. Gastric lavage and activated charcoal may be considered within one hour of ingestion. Forced diuresis, dialysis, or hemoperfusion are unlikely to be beneficial due to high protein binding.
Storage
Store below 30°C (86°F) in a dry place, protected from light and moisture. Keep in the original blister pack until use to maintain stability. Do not remove desiccant from packaging if present. Keep out of reach of children and pets. Do not use after the expiration date printed on the packaging. Properly dispose of unused or expired medication through take-back programs—do not flush or pour into drainage systems.
Disclaimer
This information is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting, changing, or stopping any medication. The prescribing physician should evaluate individual patient factors, including medical history, concomitant medications, and risk profile. Treatment decisions must balance potential benefits against risks. Not all side effects or interactions are listed here—report any adverse reactions to a healthcare provider promptly.
Reviews
Clinical studies demonstrate significant improvement in pain scores and functional indices in osteoarthritis and rheumatoid arthritis patients compared to placebo. In a 12-week randomized controlled trial (n=327), Voveran SR 100mg once daily showed non-inferiority to diclofenac sodium 50mg TID in pain reduction, with improved gastrointestinal tolerability profile. Patient-reported outcomes indicate high satisfaction with once-daily dosing convenience. Long-term observational data suggest maintained efficacy over 6-12 months of therapy, though regular monitoring is advised.